Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice.

Br J Haematol · 2025 · PMC12624152 · PMID 40916568

Europe PMC DOI

hedged sentence

0.1050

closest p · 2.1× alpha

0.1050

boldest claim

The sentences

showed a trendp = 0.105not close (p > 0.1)

End‐of‐treatment MRD negativity showed a trend towards association with a better ORR (100% vs. 69%, p = 0.105) and CR rate (90% vs. 54%, p = 0.062; Table S9 ), a trend towards association with improved PFS (2‐year PFS 90% vs. 46%, HR 0.26, 95% CI 0.07–0.95, p = 0.065), and was significantly associated with a better OS (2‐year OS 100% vs. 69%, HR 0.15, 95% CI 0.03–0.85, p = 0.031; Figure 6C,D ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.